Nature Medicine, Published online: 17 April 2026; doi:10.1038/d41591-026-00021-7 Three phase 1/2 trials show that direct editing of HBG1 and HBG2 promoters is a promising disease‑agnostic strategy for treating β‑hemoglobinopathies such as sickle-cell disease and β-thalassemia.
Nature Medicine published a clinical update in Research Highlights on 17 Apr 2026. The item focuses on New gene-editing approaches for β-hemoglobinopathies. Open the detail page to review the full original feed content.